NEX-20 human PK data shows lenalidomide slow release
Today Nanexa announced positive data from its Ph 1 NEX-20-01 study testing its slow-release lenalidomide formulation (NEX-20) in humans, confirming a controlled release of lenalidomide due to Nanexa's PharmaShell technology. The analysed samples came from nine healthy volunteers that received different doses of NEX-20 (ranging from 15 mg to 50 mg) via subcutaneous injection over a course of 21 days.
Aktuellt
SENASTE
